IQVIA (NYSE:IQV) Stock Price Expected to Rise, Evercore ISI Analyst Says

IQVIA (NYSE:IQV - Free Report) had its price objective boosted by Evercore ISI from $170.00 to $180.00 in a report published on Wednesday,Benzinga reports. The firm currently has an outperform rating on the medical research company's stock.

Several other research firms have also weighed in on IQV. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. JPMorgan Chase & Co. reduced their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. UBS Group reduced their price target on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Wall Street Zen downgraded IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $222.45.

IQVIA Price Performance

NYSE IQV traded down $2.33 during trading hours on Wednesday, reaching $162.14. 1,289,745 shares of the company's stock were exchanged, compared to its average volume of 1,654,013. The stock has a market cap of $28.05 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 1.80 and a beta of 1.30. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The firm has a fifty day moving average of $151.34 and a 200-day moving average of $172.74. IQVIA has a one year low of $134.65 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the prior year, the firm posted $2.54 earnings per share. The company's quarterly revenue was up 2.5% on a year-over-year basis. On average, equities research analysts predict that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Everpar Advisors LLC lifted its holdings in shares of IQVIA by 4.6% in the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company's stock valued at $221,000 after purchasing an additional 62 shares in the last quarter. Continuum Advisory LLC lifted its holdings in IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after acquiring an additional 64 shares during the period. Ballentine Partners LLC lifted its holdings in IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after acquiring an additional 69 shares during the period. Independent Advisor Alliance lifted its holdings in IQVIA by 4.2% during the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after acquiring an additional 72 shares during the period. Finally, ST Germain D J Co. Inc. lifted its holdings in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the period. Institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.